Neogen (NEOG)
(Delayed Data from NSDQ)
$16.78 USD
+0.73 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.78 USD
+0.73 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Earnings Season Could Be Great for Neogen (NEOG)
by Zacks Equity Research
Neogen (NEOG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Healthy Top-Line Growth Aid Jabil's (JBL) Q2 Earnings?
by Zacks Equity Research
Jabil (JBL) is likely to witness top-line expansion backed by the company's continuous innovation approach, favorable demand trends and excellent operational execution.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Neogen's (NEOG) New Launches Aid, Margin Pressure Stays
by Zacks Equity Research
Neogen (NEOG) continues to see rising revenues from the Food Safety business.
ICU Medical (ICUI) Beats Q4 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 6.67% and 0.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.
Henry Schein (HSIC) Q4 Earnings In Line, Gross Margin Up
by Zacks Equity Research
Growth in Technology and Value-added Services and the Medical segment drove Henry Schein's (HSIC) Q4 revenues.
Bruker (BRKR) Q4 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.
Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.
STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y
by Zacks Equity Research
Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.
Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Severe currency headwinds are expected to have affected Medtronic's (MDT) profitability in fiscal Q3.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases
by Zacks Equity Research
IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.
Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.
CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.
Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down
by Zacks Equity Research
Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.
McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.
Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.